Weight Loss Drug Accomplia Dangerous For People On Anti Depressants Says European Watchdog
Featured ArticleMain Category: Obesity / Weight Loss / Fitness
Also Included In: Psychology / Psychiatry; Depression
Article Date: 23 Jul 2007 - 1:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
4.23 (56 votes) |
| Healthcare Prof: | |
4.26 (19 votes) |
| Article Opinions: | 2 posts |
The European Medicines Agency (EMEA) says the weight loss drug Accomplia, which has also been shown to help smokers quit, should not be used by patients who are severely depressed or taking anti-depressants as it heightens the risk of suicide among this group.
Accomplia is made by the French pharmaceutical giant sanofi-aventis; the generic name of the drug is rimonabant. It has been authorized in the European Union since June 2006, to be used in combination with diet and exercise to help obese and overweight patients lose weight. It was not approved as a smoking cessation agent. Clinical trials showed that it could help patients lose 10 per cent of their body weight.
A warning was issued when it was approved by the EMEA informing doctors not to prescribe it to patients on anti-depressants because of risk of psychiatric side effects, and depression in particular. Information accompanying the drug indicated that doctors should not prescribe it to patients with uncontrolled serious psychiatric conditions such as major depression.
This latest warning is an upgrade, issued by the EMEA's Committee for Medicinal Products for Human Use (CHMP) following one year of monitoring the drug since its approval. The CHMP asked the manufacturer to submit all the information it had on the psychiatric side effects of the drug.
The CHMP panel met last week to review the information on Accomplia's side effects and concluded that the benefits of the drug still outweighed the risks, but not in patients with ongoing major depression or who are taking anti-depressants. As well as updating the psychiatric side effect information, they also recommended that the warning be upgraded to say that Accomplia should be stopped if the patient develops depression.
A letter is being sent to all doctors telling them about the new warning and suggesting that patients and the people who care for them should be advised of the risk of depression from taking Accomplia.
Last month, the US Food and Drug Administration (FDA) Advisory Committee for Endocrine and Metabolic Drugs (EMDAC) said that sanofi-aventis had failed to show that Accomplia (rimonabant) was safe and voted against recommending the anti-obesity treatment for use in the United States. According to a report in Britain's Daily Mail, two of the patients in a trial reviewed by the FDA committed suicide and one was suicidal. One of the patients in the trial had also tried to kill his daughter.
Sanofi-aventis withdrew their application for FDA approval of Accomplia and said it would submit a new one in due course.
The body that controls drugs in the UK, the Medicines and Healthcare products Regulatory Agency, up to the end of last month, has received 318 reports of patients being affected by side effects from taking Accomplia. The drug has been on sale in the UK since July 2006. Since then more than 40,000 Britons have used it.
The CHMP recommendation now goes to the European Commission for a final decision.
Accomplia is used by patients who are obese with a body mass index (BMI) greater than or equal to 30 kg per meter squared as part of a program that includes exercise and diet. It is also used by patients who are overweight (BMI of 27 or more) who have other risk factors such as type 2 diabetes or high levels of blood fat.
The active ingredient in Accomplia (rimonabant) is a cannabinoid receptor antagonist. This blocks the cannabinoid type 1 (CB1) receptor in the brain which helps to control food intake. Blocking the receptor makes it easier for patients to stop over-eating. CB1 receptors are also found in fat cells in the body.
Click here for Questions and Answers about Accomplia from the EMEA (PDF reader required).
For further information please go to The European Medicines Agency.
Written by: Catharine Paddock
Writer: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/articles/77548.php>
APA
http://www.medicalnewstoday.com/articles/77548.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (2)
The Accomplia - Luqaimat Combo
posted by Prof. Dr. Mohamed Elhashemy on 24 Jul 2007 at 4:46 amThe active chemical substance in Accomplia, rimonabant, is a cannabinoid receptor antagonist (CB1). Being chemical, it usually acts within a short time after intake and stays for a limited duration. Hence, a daily supply of the drug is needed for a year-long to get its weight loss effect. This long duration of intake could be the reason behind the few cases of suicidal attempts. The site of action of Accomplia is mainly on the hippocampus, which controls the food addiction.
The Luqaimat Training Technique (LTT) innovated by me in 2005 (referenced for in my previous opinions in Medical News Today in 13, 18, 19, & 22 July 2007) acts on the same brain site but with a different mode of action that is psychobiological induction of hippocampul neuroplasticity. A few weeks is needed to the auditory visual and psychological cues to get the maximum effective.
On a relevant topic, a research was done at the University of Pennsylvania, School of Medicine published in Nov 2005 on the combining effect of Meridia and weight loss counseling sessions cited that the results of the combo was better than the summation of the two methods if applied separately.
Similarly, I think that if we put the advantage of the fast effect of Accomplia at the beginning of the weight loss program together with the advantage of the gradual effect of LTT, which appears after few weeks, we will gain a synergistic effect on hippocampul neurplasticity. This combo diet will be a great progress in the field of managing extreme obesity.
Instead of disapproving the Accomplia as a long-term weight loss drug due to its depressive effect, we can use it for initiation of controlling hunger feeling at the hippocampul level for a short-term period (e.g. 3 weeks) to be accompanied by Luqaimat Training Technique for a long-term period.
Excellant Method
posted by Amina Abd Elkhair ReHAN on 5 Aug 2007 at 12:54 amI think this issue is an excellent method to lose weight, drugs are harmful & depressive but when I feel free to eat what ever I want when ever I want I’ll feel better at the same time I’ll control my self to preserves my diet with this wonderful feeling of being free.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
